435 related articles for article (PubMed ID: 25684964)
1. Gastrointestinal neuroendocrine tumors treated with high dose octreotide-LAR: a systematic literature review.
Broder MS; Beenhouwer D; Strosberg JR; Neary MP; Cherepanov D
World J Gastroenterol; 2015 Feb; 21(6):1945-55. PubMed ID: 25684964
[TBL] [Abstract][Full Text] [Related]
2. Association of dose escalation of octreotide long-acting release on clinical symptoms and tumor markers and response among patients with neuroendocrine tumors.
Al-Efraij K; Aljama MA; Kennecke HF
Cancer Med; 2015 Jun; 4(6):864-70. PubMed ID: 25727756
[TBL] [Abstract][Full Text] [Related]
3. Clinical benefits of above-standard dose of octreotide LAR in patients with neuroendocrine tumors for control of carcinoid syndrome symptoms: a multicenter retrospective chart review study.
Strosberg JR; Benson AB; Huynh L; Duh MS; Goldman J; Sahai V; Rademaker AW; Kulke MH
Oncologist; 2014 Sep; 19(9):930-6. PubMed ID: 25096997
[TBL] [Abstract][Full Text] [Related]
4. Dose escalation of octreotide LAR is safe and effective in patients with advanced gastrointestinal neuroendocrine tumours for control of symptoms and tumor progression.
Verslype C
Acta Gastroenterol Belg; 2011 Mar; 74(1):93-4. PubMed ID: 21563661
[No Abstract] [Full Text] [Related]
5. High-dose octreotide acetate for management of gastroenteropancreatic neuroendocrine tumors.
Chadha MK; Lombardo J; Mashtare T; Wilding GE; Litwin A; Raczyk C; Gibbs JF; Kuvshinoff B; Javle MM; Iyer RV
Anticancer Res; 2009 Oct; 29(10):4127-30. PubMed ID: 19846960
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of octreotide long-acting repeatable in neuroendocrine tumors: RADIANT-2 placebo arm post hoc analysis.
Strosberg JR; Yao JC; Bajetta E; Aout M; Bakker B; Hainsworth JD; Ruszniewski PB; Van Cutsem E; Öberg K; Pavel ME
Endocr Relat Cancer; 2015 Dec; 22(6):933-40. PubMed ID: 26373569
[TBL] [Abstract][Full Text] [Related]
7. Cost reduction from resolution/improvement of carcinoid syndrome symptoms following treatment with above-standard dose of octreotide LAR.
Huynh L; Totev T; Vekeman F; Neary MP; Duh MS; Benson AB
J Med Econ; 2017 Sep; 20(9):945-951. PubMed ID: 28562131
[TBL] [Abstract][Full Text] [Related]
8. Effect of octreotide LAR dose and weight on octreotide blood levels in patients with neuroendocrine tumors.
Woltering EA; Mamikunian PM; Zietz S; Krutzik SR; Go VL; Vinik AI; Vinik E; O'Dorisio TM; Mamikunian G
Pancreas; 2005 Nov; 31(4):392-400. PubMed ID: 16258376
[TBL] [Abstract][Full Text] [Related]
9. Shortened interval of long-acting octreotide administration is effective in patients with well-differentiated neuroendocrine carcinomas in progression on standard doses.
Ferolla P; Faggiano A; Grimaldi F; Ferone D; Scarpelli G; Ramundo V; Severino R; Bellucci MC; Camera LM; Lombardi G; Angeletti G; Colao A
J Endocrinol Invest; 2012 Mar; 35(3):326-31. PubMed ID: 21757992
[TBL] [Abstract][Full Text] [Related]
10. Octreotide long-acting repeatable use among elderly patients with carcinoid syndrome and survival outcomes: a population-based analysis.
Shen C; Shih YC; Xu Y; Yao JC
Cancer; 2014 Jul; 120(13):2039-49. PubMed ID: 24676892
[TBL] [Abstract][Full Text] [Related]
11. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.
Rinke A; Müller HH; Schade-Brittinger C; Klose KJ; Barth P; Wied M; Mayer C; Aminossadati B; Pape UF; Bläker M; Harder J; Arnold C; Gress T; Arnold R;
J Clin Oncol; 2009 Oct; 27(28):4656-63. PubMed ID: 19704057
[TBL] [Abstract][Full Text] [Related]
12. Everolimus plus octreotide long-acting repeatable in patients with colorectal neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-2 study.
Castellano D; Bajetta E; Panneerselvam A; Saletan S; Kocha W; O'Dorisio T; Anthony LB; Hobday T;
Oncologist; 2013; 18(1):46-53. PubMed ID: 23263288
[TBL] [Abstract][Full Text] [Related]
13. Improved survival with higher doses of octreotide long-acting release in gastroenteropancreatic neuroendocrine tumors.
Lau SC; Abdel-Rahman O; Cheung WY
Med Oncol; 2018 Aug; 35(9):123. PubMed ID: 30078166
[TBL] [Abstract][Full Text] [Related]
14. Use of octreotide long acting repeatable (LAR) as second-line therapy in advanced neuroendocrine tumors in different clinical settings: an Italian Delphi survey.
Falconi M; Fazio N; Ferone D; Versari A
Expert Opin Pharmacother; 2020 Dec; 21(18):2317-2324. PubMed ID: 32990061
[TBL] [Abstract][Full Text] [Related]
15. Clinical value of monitoring plasma octreotide levels during chronic octreotide long-acting repeatable therapy in carcinoid patients.
Woltering EA; Salvo VA; O'Dorisio TM; Lyons J; Li G; Zhou Y; Seward JR; Go VL; Vinik AI; Mamikunian P; Mamikunian G
Pancreas; 2008 Jul; 37(1):94-100. PubMed ID: 18580450
[TBL] [Abstract][Full Text] [Related]
16. Evaluating the characteristics and the management of patients with neuroendocrine tumors receiving octreotide LAR during a 6-year period.
Anthony L; Vinik AI
Pancreas; 2011 Oct; 40(7):987-94. PubMed ID: 21697761
[TBL] [Abstract][Full Text] [Related]
17. Everolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors: analysis of the phase 3, randomized, placebo-controlled RADIANT-2 study.
Fazio N; Granberg D; Grossman A; Saletan S; Klimovsky J; Panneerselvam A; Wolin EM
Chest; 2013 Apr; 143(4):955-962. PubMed ID: 23187897
[TBL] [Abstract][Full Text] [Related]
18. Antiproliferative effect of somatostatin analogs in gastroenteropancreatic neuroendocrine tumors.
Strosberg J; Kvols L
World J Gastroenterol; 2010 Jun; 16(24):2963-70. PubMed ID: 20572298
[TBL] [Abstract][Full Text] [Related]
19. Antiproliferative Effect of Above-Label Doses of Somatostatin Analogs for the Management of Gastroenteropancreatic Neuroendocrine Tumors.
Diamantopoulos LN; Laskaratos FM; Kalligeros M; Shah R; Navalkissoor S; Gnanasegaran G; Banks J; Smith J; Jacobs B; Galanopoulos M; Mandair D; Caplin M; Toumpanakis C
Neuroendocrinology; 2021; 111(7):650-659. PubMed ID: 32541155
[TBL] [Abstract][Full Text] [Related]
20. Prescribing Characteristics of Octreotide Immediate-Release and Long-Acting Release in Patients with Neuroendocrine Tumors.
Cheng Y; Anthony L; Delcher C; Moga DC; Chauhan A; Huang B; Adams V
Oncologist; 2023 Jun; 28(6):479-485. PubMed ID: 36994847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]